Manjulika Das
Manjulika Das
Paul Adepoju
Paul Adepoju
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus [0.03%]
保乳治疗后同侧乳腺二次癌的局部管理：国际德尔菲共识
Jean-Michel Hannoun-Levi,Julie A Margenthaler,Bethany Anderson et al.
Jean-Michel Hannoun-Levi et al.
Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies. This project, endorsed by ...
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research [0.03%]
妇科肿瘤交互组宫颈癌临床研究首次共识会议共识声明
Babita Kataria,Asima Mukhopadhyay,Ana Oaknin et al.
Babita Kataria et al.
The rigorous conduct of well designed clinical trials is critical to improving outcomes for patients with gynaecological cancers. The Gynecologic Cancer InterGroup (GCIG) has promoted collaboration and harmonisation to guide clinical trials...
Advancing oncology education in low-income and middle-income African settings: global insights for local action [0.03%]
低收入和中等收入非洲国家肿瘤学教育的进展：全球视角下的本地行动
Suman Shrestha,Chinelo Onwualu Chigbo,Shannon O&#x;Reilly et al.
Suman Shrestha et al.
Cancer incidence and mortality are rising globally, with their burden falling disproportionately on low-income and middle-income countries. Africa faces major gaps in oncology education and workforce development, limiting access to high-qua...
Risks of modelling cancer outcomes when no data exist - Authors' reply [0.03%]
当无数据时对癌症结局进行建模的风险——作者回应
Zachary J Ward
Zachary J Ward
Atif Kamal
Atif Kamal
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial [0.03%]
一项单臂3期试验：在卡介菌免疫治疗无效的高危非肌层浸润性膀胱癌（伴有原位癌）患者中使用瘤内注射Cretostimogene Grenadenorepvec溶瘤免疫疗法（BOND-003队列C）
Mark D Tyson nd,Jong-Kil Nam,Shreyas S Joshi et al.
Mark D Tyson nd et al.
Background: There are few bladder-sparing treatment options for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer that are effective and have a manageable adverse event profile. Cretostimogene grenadenorepve...
Clinical Trial
The Lancet. Oncology. 2026 Aug;27(8):983-993. DOI:10.1016/S1470-2045(26)00194-4 2026
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial [0.03%]
乳腺癌根治术后胸壁放射治疗的五年生活质量结果：一项随机对照III期试验（SUPREMO）
Galina Velikova,Nicola S Russell,Linda Jane Williams et al.
Galina Velikova et al.
Background: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (...
Clinical Trial
The Lancet. Oncology. 2026 Aug;27(8):959-972. DOI:10.1016/S1470-2045(26)00122-1 2026